-
1دورية أكاديمية
المؤلفون: D. J Ouyang, Q. T Chen, M. Anwar, N. Xie, Q. C. Ouyang, P. Z. Fan, L. Y. Qian, G. N. Chen, E. X. Zhou, L. Guo, X. W. Gu, B. N. Ding, X. H. Yang, L. P. Liu, C. Deng, Z. Xiao, J. Li, Y. Q. Wang, S. Zeng, Shouman Wang, Wenjun Yi
المصدر: Frontiers in Pharmacology, Vol 12 (2021)
مصطلحات موضوعية: pyrotinib, lapatinib-treated, lapatinib-naive, HER2 breast cancer, metastases, Therapeutics. Pharmacology, RM1-950
العلاقة: https://www.frontiersin.org/articles/10.3389/fphar.2021.682568/fullTest; https://doaj.org/toc/1663-9812Test; https://doaj.org/article/86d998d85d6c49fd9045d899d8309742Test
الإتاحة: https://doi.org/10.3389/fphar.2021.682568Test
https://doaj.org/article/86d998d85d6c49fd9045d899d8309742Test -
2صورة
المؤلفون: D. J Ouyang (11335068), Q. T Chen (11335071), M. Anwar (10404872), N. Xie (7698083), Q. C. Ouyang (11335074), P. Z. Fan (11335077), L. Y. Qian (11335080), G. N. Chen (11335083), E. X. Zhou (11335086), L. Guo (4453888), X. W. Gu (11335089), B. N. Ding (11335092), X. H. Yang (11335095), L. P. Liu (11335098), C. Deng (6652631), Z. Xiao (3604901), J. Li (51350), Y. Q. Wang (4918831), S. Zeng (11335101), Shouman Wang (3842485), Wenjun Yi (8888957)
مصطلحات موضوعية: Pharmacology, Basic Pharmacology, Clinical Pharmacology and Therapeutics, Clinical Pharmacy and Pharmacy Practice, Pharmaceutical Sciences, Pharmacogenomics, Toxicology (incl. Clinical Toxicology), Pharmacology and Pharmaceutical Sciences not elsewhere classified, pyrotinib, lapatinib-treated, lapatinib-naive, HER2 breast cancer, metastases
-
3صورة
المؤلفون: D. J Ouyang, Q. T Chen, M. Anwar, N. Xie, Q. C. Ouyang, P. Z. Fan, L. Y. Qian, G. N. Chen, E. X. Zhou, L. Guo, X. W. Gu, B. N. Ding, X. H. Yang, L. P. Liu, C. Deng, Z. Xiao, J. Li, Y. Q. Wang, S. Zeng, Shouman Wang, Wenjun Yi
مصطلحات موضوعية: Pharmacology, Basic Pharmacology, Clinical Pharmacology and Therapeutics, Clinical Pharmacy and Pharmacy Practice, Pharmaceutical Sciences, Pharmacogenomics, Toxicology (incl. Clinical Toxicology), Pharmacology and Pharmaceutical Sciences not elsewhere classified, pyrotinib, lapatinib-treated, lapatinib-naive, HER2 breast cancer, metastases
الإتاحة: https://doi.org/10.3389/fphar.2021.682568.s001Test
https://figshare.com/articles/figure/Image1_The_Efficacy_of_Pyrotinib_as_a_Third-_or_Higher-Line_Treatment_in_HER2-Positive_Metastatic_Breast_Cancer_Patients_Exposed_to_Lapatinib_Compared_to_Lapatinib-Naive_Patients_A_Real-World_Study_pdf/16443816Test